| 本文已被：浏览 2313次 下载 2705次 |
码上扫一扫！ |
| p63与表皮生长因子受体突变肺鳞癌患者生存的关系 |
| 王碧波1,韩一平1*,万善志1,黄玲2,马大烈2,郑建明2,李强1 |
|
|
(1. 第二军医大学长海医院呼吸内科, 上海 200433;
2. 第二军医大学长海医院病理科, 上海 200433
*通信作者) |
|
| 摘要: |
| 目的 检测表皮生长因子受体（EGFR）在肺鳞癌患者中的突变率，并分析p63与EGFR突变肺鳞癌患者生存的关系。方法 收集2010年2月至2013年3月在我院初治的肺鳞癌患者的组织样本，用直接测序法检测EGFR突变情况，免疫组织化学法检测p63的表达。随访患者，记录患者的总生存时间（OS），评价EGFR突变和p63表达对患者生存的影响。结果 所有病理组织确诊为肺鳞癌的262例患者中，16例（6.1%）有EGFR突变 ，其中外显子19位点缺失7例，外显子21 L858R点突变9例，未见外显子18和20突变。与传统意义上的肺鳞癌患者相比，EGFR突变的肺鳞癌患者女性和非吸烟者所占比例较高。p63部分阳性的EGFR突变患者（n=4）的OS为11.28（95%CI：9.33～15.23）个月，p63阳性的EGFR突变患者（n=11）的OS 为5.93（95%CI：1.75～8.39）个月，两者差异有统计学意义（P=0.039）。结论 肺鳞癌患者EGFR突变率为6.1%，均为外显子19和21敏感突变。p63部分阳性的EGFR突变患者比p63阳性EGFR突变患者生存期更长。 |
| 关键词: p63 表皮生长因子受体 肺肿瘤 鳞状细胞癌 |
| DOI：10.3724/SP.J.1008.2014.00378 |
| 投稿时间：2013-11-04修订日期：2014-01-09 |
| 基金项目: |
|
| Relationship between p63 expression and survival of squamous lung cancer patients with mutatant epidermal growth factor receptor |
| WANG Bi-bo1,HAN Yi-ping1*,WAN Shan-zhi1,HUANG Ling2,MA Da-lie2,ZHENG Jian-ming2,LI Qiang1 |
(1. Department of Respiratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;
2. Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
*Corresponding author.) |
| Abstract: |
| Objective To detect the mutation rate of epidermal growth factor receptor (EGFR) in squamous carcinoma (SQC) of lung and to exam the relationship between p63 and survival of SQC patients with EGFR mutation. Methods SQC specimens were collected from the patients who received their initial treatment in our hospital between February 2010 and March 2013. The incidence of EGFR mutations was analyzed by automated direct sequencing, and immunohistochemical method was used to observe p63 expression. The patients were followed up and the impact of EGFR mutation and p63 expression upon survival of SQC patients was evaluated. Results Among the 262 histological diagnosed SQC patients, 16 (6.1%) had EGFR mutations, including exon 19 deletion (7 of 16 patients, 43.8%) and L858R point mutation in exon 21 (9 of 16, 56.2%), with no mutation of exon 18 and 20. SQC patients with EGFR mutations, compared with other SQC patients, had more females and non-smokers. The median overall survival (OS) time of 4 EGFR-mutated patients with p63 partial positive expression was 11.28 months (95% CI: 9.33-15.23 months), which was significantly longer than that of 11 EGFR-mutated patients with p63 positive expression (5.93 months [95% CI: 1.75-8.39 months], P=0.039). Conclusion EGFR mutation rate is 6.1% in our study, with all being exon 19 and 21 mutations. Patients presenting partial positive p63 expression have longer survival time than those presenting p63 positive expression. |
| Key words: p63 epidermal growth factor receptor lung neoplasms squamous cell carcinoma |
